Going-concern uncertainty
The company has no recurring revenue and expects continued losses unless it secures financing or a strategic partnership.
- Scope
- Corporate survival and ability to fund operations
- Materiality
- high
LadRx Corp
LadRx Corp is a Delaware-based biopharmaceutical research company focused on oncology drug discovery and clinical development. Its core platform, LADR™, is designed to target chemotherapeutic drugs to solid tumors while reducing off-target toxicities, and the company also developed a companion diagnostic, ACDx™, to identify patients most likely to benefit from treatment.
0.37
0.37
| % | |
|---|---|
| LADR™ oncology therapeutics | 0% Targeted anti-cancer drug candidates designed to deliver chemotherapeutic payloads to solid tumors and reduce toxicity. |
| Companion diagnostics | 0% ACDx™ diagnostic tools intended to identify patients most likely to respond to the company’s drug candidates. |
| Licensing, royalties and milestones | 100% Contractual rights to receive milestone, royalty and related payments from partnered assets and license agreements. |
| Corporate and administrative services | 0% Historical management, consulting and administrative support provided to the Centurion subsidiary structure. |
LadRx does not currently operate as a commercial drug seller; its economic counterparties are primarily pharmaceutical...
- Pharmaceutical licensing partnersprimary
Companies that license LADR-based assets or related rights to advance oncology programs and commercialize them.
- Strategic development partnersprimary
Biopharma collaborators that may fund trials, share development risk, or enter joint ventures around the platform.
- Royalty and milestone counterpartiessecondary
Partners obligated to pay contingent consideration under prior license or assignment agreements.
- Capital providersprimary
Equity investors, lenders, or other financing sources needed to sustain operations and development work.
LadRx is headquartered in Los Angeles, California, and is incorporated in Delaware. Its historical research footprint...
- •Head office in Los Angeles, California
- •Incorporated in Delaware
- •Historical discovery lab in Freiburg, Germany
- •International exposure through patents and licensing rights
- •No disclosed country revenue mix; company has no recurring revenue
The company’s strategy is to preserve and monetize the LADR platform through strategic partnerships, licensing, royalty...
01
Secure financing or strategic partnershipshort-term
The company has no recurring revenue and needs external capital to continue operating.
02
Monetize LADR intellectual propertymedium-term
Licensing and partnering are the main paths to value creation for a pre-commercial biotech.
03
Advance lead oncology candidatesmedium-term
Clinical progress is needed to improve partnering leverage and long-term asset value.
LadRx is a pre-revenue biotech with substantial going-concern risk, so its survival depends on successful financing or...
Clinical development failure
LADR candidates are still dependent on preclinical and future clinical success, which is uncertain in oncology.
- Scope
- LADR-7 to LADR-10 pipeline
- Materiality
- high
Regulatory approval risk
Drug candidates and any derived products require FDA and other regulatory approvals before commercialization.
- Scope
- Arimoclomol-related contingent payments and future product pathways
- Materiality
- high
Intellectual property risk
The business depends on patent protection and enforceability of its LADR technology and related rights.
- Scope
- Domestic and international patent portfolio
- Materiality
- medium
Counterparty and monetization risk
Royalty and milestone receipts depend on partner performance and contractual triggers, which may not occur.
- Scope
- License and assignment agreements
- Materiality
- medium
Royalty monetization accounting
Affects reported revenue, other income, and operating performance comparability
Stock-based compensation
Impacts operating loss and non-cash expense trends
Impairment of long-lived assets and intangibles
Could trigger write-downs and reduce asset values
R&D and clinical trial accrual estimates
Affects quarterly expense recognition and liabilities
Going-concern disclosure
Signals liquidity risk and affects valuation assumptions
: 28.4.2026